


AMENDMENTS TO AND LISTING OF CLAIMS

1. (Currently amended) A compound of formula I:




wherein

R_a is H; C₁₋₄-alkyl; or C₁₋₄-alkyl substituted by OH, NH₂, NHC₁₋₄-alkyl or N([[di-

4-alkyl)₂;

R_b is H; halogen; C₁₋₆-alkyl; or C₁₋₆-alkoxy, and

R is a radical of formula (a):



wherein

R₁ is piperazine or 4-methyl-piperazin-1-yl; and

R₂ is H; halogen; C₁₋₄-alkyl; C₁₋₄-alkoxy; CF₃; nitrile; nitro; or amino;
or a salt thereof.


2. (Original) A compound according to claim 1 wherein R_a is H, methyl, ethyl, or isopropyl, or a salt thereof.

3. (Previously presented) A compound according to claim 1 wherein R_b is H, Cl, methyl or ethyl, or a salt thereof.

4. (Canceled)

5. (Currently amended) A compound according to claim 1, wherein R_2 is H; Cl, F; CF_3 ; nitrile; nitro; or amino; or a salt thereof.

6. (Previously presented) A process for the preparation of a compound of formula I according to claim 1, which process comprises reacting a compound of formula II



wherein R_a and R_b are as defined in claim 1,
with a compound of formula III



wherein R is as defined in claim 1,
and, where required, converting the resulting compound of formula I obtained in free form to a salt form or vice versa, as appropriate.

7. (Previously presented) A compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form for use as a pharmaceutical.

8. (Previously presented) A pharmaceutical composition comprising a compound of formula I of claim 1, in free form or in a pharmaceutically acceptable salt form, in association with a pharmaceutically acceptable diluent or

carrier therefor.

9. (Canceled)

10. (Previously presented) A method for preventing or treating acute or chronic transplant rejection in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claims 1 or a pharmaceutically acceptable salt thereof.

11. (Previously presented) A method for treating acute or chronic transplant rejection, psoriasis, or uveitis, in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I of claim 1 or a pharmaceutically acceptable salt thereof.

12. (New) A compound according to Claim 1 that is 3-(1H-indol-3-yl)-4-[6-(4-methyl-piperazin-1-yl)-3-trifluoromethyl-pyridin-2-yl]-pyrrole-2,5-dione, or a pharmaceutically-acceptable salt thereof.